Pharmacokinetics of H3B-6545 in patients with locally advanced or metastatic estrogen receptor-positive HER2 negative breast cancer (ER+ and HER2-BC)

被引：0
|
作者：
Majid, Oneeb [1 ]
Xiao, Jianjun Alan [2 ]
Sahmoud, Tarek [2 ]
Yasuda, Sanae [3 ]
Cantagallo, Lisa [2 ]
Hamilton, Erika P. [4 ]
Pluard, Timothy [5 ]
Juric, Dejan [6 ]
Gualberto, Antonio [2 ]
Husseiin, Ziad [1 ]
机构：
[1] Eisai, Hatfield, Herts, England
[2] H3 Biomed, Cambridge, MA USA
[3] Eisai Inc, Woodcliff Lake, NJ USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] St Lukes Canc Inst, Kansas City, MO USA
[6] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS12-15
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer
    Pegram, Mark
    Jackisch, Christian
    Johnston, Stephen R. D.
    NPJ BREAST CANCER, 2023, 9 (01)
  • [22] The Evolving Use of SERDs in Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Jeselsohn, Rinath M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (07) : 428 - 431
  • [23] Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer
    Mark Pegram
    Christian Jackisch
    Stephen R. D. Johnston
    npj Breast Cancer, 9
  • [24] HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?
    Batra, Atul
    Kumar, Akash
    BREAST, 2021, 55 : 136 - 136
  • [25] ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in women and men with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC)
    Rugo, Hope S.
    Bardia, Aditya
    Cortes, Javier
    Curigliano, Giuseppe
    Hamilton, Erika
    Hurvitz, Sara A.
    Loibl, Sibylle
    Kummel, Sherko
    Scartoni, Simona
    Matheny, Shannon
    Theall, Kathy Puyana
    O'shaughnessy, Joyce
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 32 - 32
  • [26] EFFECT OF ADJUVANT ENDOCRINE THERAPY ON ESTROGEN RECEPTOR-NEGATIVE, PROGESTERONE RECEPTOR-POSITIVE AND HER2 NEGATIVE BREAST CANCER PATIENTS
    Shen, Jun
    Wang, Lin-bo
    Teng, Rong-yue
    Shen, Jian-guo
    ACTA MEDICA MEDITERRANEA, 2022, 38 (03): : 1595 - 1600
  • [27] A retrospective, non-interventional study of breast cancer patients diagnosed with ER+/HER2 negative, locally advanced or metastatic breast cancer treated with palbociclib in Denmark
    Garly, Rasmus
    Berg, Tobias
    Jensen, Maj-Britt
    Knoop, Ann
    Volmer, Lone
    Glavicic, Vesna
    Khan, Humma
    Poulsen, Peter Bo
    Olsen, Jens
    Kuemler, Iben
    ACTA ONCOLOGICA, 2023, 62 (03) : 290 - 297
  • [28] The somatic mutation profile of estrogen receptor-positive HER2-negative metastatic breast cancer in Brazilian patients
    Reinert, Tomas
    do Rego, Fernanda Orpinelli
    Silva, Matheus Costa e
    Rodrigues, Amanda Muniz
    Koyama, Fernanda Christtanini
    Goncalves, Aline Coelho
    Pauletto, Maiane Maria
    de Carvalho Oliveira, Leandro Jonata
    de Resende, Cristiano Augusto Andrade
    Landeiro, Luciana Castro Garcia
    Barrios, Carlos Henrique
    Mano, Max Senna
    Dienstmann, Rodrigo
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [29] Characteristics of patients (pts) with previously treated, oestrogen receptor-positive, HER2-negative advanced breast cancer (ER+, HER2-aBC) who had rapid progression (RP) in acelERA BC
    Martin Jimenez, M.
    Hilz, S.
    Collier, A.
    Chibly, A.
    Sohn, J.
    Bardia, A.
    Lim, E.
    Mac Gregor, M. Chavez
    Martinalbo, J.
    Perez-Moreno, P. D.
    Moore, H. M.
    ANNALS OF ONCOLOGY, 2023, 34 : S356 - S357
  • [30] Elacestrant combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC): Preliminary data from ELEVATE, a phase Ib/II, open-label, umbrella study
    Rugo, H. S.
    O'Shaughnessy, J.
    Cortes, J.
    Bardia, A.
    Hamilton, E. P.
    Hurvitz, S. A.
    Kaklamani, V.
    Mchayleh, W.
    Romero, P. Munoz
    Vallespir, B. Piza
    Wasserman, T.
    Theall, K. P.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2024, 35 : S372 - S373
12345